CELESTE

CELESTE is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.ABCA4 (AAVB-039) administered sub-retinally in subjects with Stargardts disease.